Overview
Act Early. Treat Advanced. The New Era of LDL-C Management is a one-hour CME session from the Saudi Heart Association (SHA) and the Saudi Atherosclerosis Working Group. It runs on Tuesday 29 September 2026, 08:00–09:00 (Riyadh time) and is accredited for 2 CME hours. Registration is free through the official registration page. Sanofi supports the session and Konoz Retaj is the event partner.
LDL cholesterol is the most modifiable driver of atherosclerotic cardiovascular disease, yet many high-risk patients in the Kingdom still don't reach guideline targets. The session makes the case for treating early and treating intensively: acting on LDL-C before events happen, and moving quickly to combination and advanced lipid-lowering therapy when statins alone aren't enough.
Scientific programme
| Time | Session | Speaker |
|---|
| 08:00 – 08:25 | The importance of early LDL-C management | Dr Abdulaziz Abdulmalik Aldheshe |
| 08:25 – 08:50 | Recent updates on lipid-lowering treatment | Dr Ali Altebainawi |
| 08:50 – 09:00 | Q&A | All faculty |
Faculty
- Dr Abdulaziz Abdulmalik Aldheshe, Lipidologist and Preventive Cardiologist Consultant, King Faisal Specialist Hospital & Research Centre (KFSHRC)
- Dr Ali Altebainawi, Consultant Cardiology Clinical Pharmacist, Hail Health Cluster
Key topics
- The "lower for longer" principle and cumulative LDL exposure
- Risk-based LDL-C targets from current ESC/EAS and regional guidance
- Ezetimibe, PCSK9 inhibitors, inclisiran and bempedoic acid in practice
- Overcoming treatment inertia and improving adherence
- The clinical pharmacist's role in lipid clinics
Who should attend
Cardiologists, internal medicine and family physicians, endocrinologists, clinical pharmacists, residents and fellows, and nurses working in cardiovascular prevention.
Event page: https://saudi-heart.com/act-early-treat-advanced/
